Brief: Biomx Announces Dosing Of The First Two Patients In Phase 1B/2A Study Of Bx004 For Treatment Of Chronic Respiratory Infections In Patients With Cystic Fibrosis
June 27 (Reuters) - Biomx Inc PHGE.A :
* BIOMX ANNOUNCES DOSING OF THE FIRST TWO PATIENTS IN PHASE
1B/2A
STUDY OF BX004 FOR TREATMENT OF CHRONIC RESPIRATORY INFECTIONS
IN PATIENTS WITH CYSTIC FIBROSIS
* BIOMX INC - DATA READOUT FROM PART I OF STUDY EXPECTED IN
3Q
2022
Source text for Eikon: ID:nBw3DmjZwa
Further company coverage: PHGE.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomx
See all newsBrief: Biomx Inc - Buys 100% Of Zorronet From Water Io - SEC Filing
Brief: BiomX Obtains Option To Acquire Control Of Israeli Laser-Radar Counter-Drone System
Brief: Biomx Adds Former Mossad Deputy To Advisory Board
Brief: Biomx Inc - Jonathan Solomon Resigns As CEO And Board Member Effective March 4, 2026 - SEC Filing
Brief: BiomX Says Unaware of Any Undisclosed Developments Amid Unusual Stock Trading